Exercise Therapy Rescues Skeletal Muscle Dysfunction and Exercise Intolerance in Cardiometabolic HFpEF

IF 8.4 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

JACC: Basic to Translational Science Pub Date : 2024-12-01 DOI:10.1016/j.jacbts.2024.07.009

Heather Quiriarte MS , Robert C. Noland PhD , James E. Stampley PhD , Gregory Davis MS , Zhen Li PhD , Eunhan Cho PhD , Youyoung Kim MS , Jake Doiron BS , Guillaume Spielmann PhD , Sujoy Ghosh PhD , Sanjiv J. Shah MD , Brian A. Irving PhD , David J. Lefer PhD , Timothy D. Allerton PhD

{"title":"Exercise Therapy Rescues Skeletal Muscle Dysfunction and Exercise Intolerance in Cardiometabolic HFpEF","authors":"Heather Quiriarte MS , Robert C. Noland PhD , James E. Stampley PhD , Gregory Davis MS , Zhen Li PhD , Eunhan Cho PhD , Youyoung Kim MS , Jake Doiron BS , Guillaume Spielmann PhD , Sujoy Ghosh PhD , Sanjiv J. Shah MD , Brian A. Irving PhD , David J. Lefer PhD , Timothy D. Allerton PhD","doi":"10.1016/j.jacbts.2024.07.009","DOIUrl":null,"url":null,"abstract":"<div><div>Exercise intolerance, a hallmark of heart failure with preserved ejection fraction (HFpEF) exacerbated by obesity, involves unclear mechanisms related to skeletal muscle metabolism. In a “2-hit” model of HFpEF, we investigated the ability of exercise therapy (voluntary wheel running) to reverse skeletal muscle dysfunction and exercise intolerance. Using state-of-the-art metabolic cages and a multiomic approach, we demonstrate exercise can rescue dysfunctional skeletal muscle lipid and branched-chain amino acid oxidation and restore exercise capacity in mice with cardiometabolic HFpEF. These results underscore the importance of skeletal muscle metabolism to improve exercise intolerance in HFpEF.</div></div>","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"9 12","pages":"Pages 1409-1425"},"PeriodicalIF":8.4000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11733766/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC: Basic to Translational Science","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452302X24002894","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Exercise intolerance, a hallmark of heart failure with preserved ejection fraction (HFpEF) exacerbated by obesity, involves unclear mechanisms related to skeletal muscle metabolism. In a “2-hit” model of HFpEF, we investigated the ability of exercise therapy (voluntary wheel running) to reverse skeletal muscle dysfunction and exercise intolerance. Using state-of-the-art metabolic cages and a multiomic approach, we demonstrate exercise can rescue dysfunctional skeletal muscle lipid and branched-chain amino acid oxidation and restore exercise capacity in mice with cardiometabolic HFpEF. These results underscore the importance of skeletal muscle metabolism to improve exercise intolerance in HFpEF.

查看原文本刊更多论文

运动疗法可拯救心脏代谢性HFpEF的骨骼肌功能障碍和运动不耐受。

运动不耐受是因肥胖而加重的保留射血分数（HFpEF）心力衰竭的标志，其与骨骼肌代谢的相关机制尚不清楚。在HFpEF的“2-hit”模型中，我们研究了运动疗法（自主轮跑）逆转骨骼肌功能障碍和运动不耐受的能力。使用最先进的代谢笼和多组学方法，我们证明运动可以挽救功能失调的骨骼肌脂质和支链氨基酸氧化，并恢复心脏代谢性HFpEF小鼠的运动能力。这些结果强调了骨骼肌代谢对改善HFpEF运动不耐受的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

JACC: Basic to Translational Science CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

14.20

自引率

1.00%

发文量

161

审稿时长

16 weeks

期刊介绍： JACC: Basic to Translational Science is an open access journal that is part of the renowned Journal of the American College of Cardiology (JACC). It focuses on advancing the field of Translational Cardiovascular Medicine and aims to accelerate the translation of new scientific discoveries into therapies that improve outcomes for patients with or at risk for Cardiovascular Disease. The journal covers thematic areas such as pre-clinical research, clinical trials, personalized medicine, novel drugs, devices, and biologics, proteomics, genomics, and metabolomics, as well as early phase clinical trial methodology.